Immunoexpression of multidrug-resistance protein 2 and cyclooxygenase 2 in medullary thyroid carcinomas

Rosaria Maddalena Ruggeri1, Salvatore Sciacchitano, Enrica Vitarelli

  • 1Sezione di Endocrinologia, Dipartimento Clinico-Sperimentale di Medicina e Farmacologia, Policlinico Universitario, Messina, Italy.

Abstract

Insights

Multidrug-resistance protein 2 (MRP2) and cyclooxygenase 2 (COX2) expression in medullary thyroid carcinoma (MTC) correlates with tumor stage. High MRP2 and low COX2 may predict resistance to chemotherapy in advanced MTC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chemoresistance in medullary thyroid carcinoma (MTC) is linked to multidrug-resistance proteins (MRPs).
  • Cyclooxygenase 2 (COX2) upregulates MRP1, but MRP2's role in MTC chemoresistance is unknown.
  • MRP1 is overexpressed in MTC but not linked to doxorubicin/cisplatin resistance, unlike MRP2.

Purpose of the Study:

  • To investigate the expression of MRP2 and COX2 in medullary thyroid carcinoma.
  • To correlate MRP2 and COX2 expression with pTNM staging and clinical stage in MTC.

Main Methods:

  • Immunohistochemical analysis of MRP2 and COX2 expression in 12 MTC primary tumors and 6 lymph node metastases.
  • Correlation of protein expression with pTNM and clinical stage.

Main Results:

  • MRP2 and COX2 were detected in MTC tumors and metastases.
  • MRP2 expression was higher in advanced pTNM stage T4 MTCs and metastases.
  • COX2 expression was higher in earlier stages (T2-T3) and decreased with advanced stage; MRP2 and COX2 showed inverse correlation.

Conclusions:

  • MRP2 and COX2 expression levels correlate with pTNM stage in MTC.
  • Elevated MRP2 and reduced COX2 expression may contribute to chemoresistance in advanced MTC.
  • Assessing MRP2 and COX2 expression patterns could help predict MTC chemosensitivity.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...